<DOC>
	<DOCNO>NCT00767559</DOCNO>
	<brief_summary>The purpose research find good way prevent post operative development clot deep vein leg ( also call Deep Vein Thrombosis DVT ) . DVT cause redness , swell , pain involve leg ( ) . Long-term complication may include permanent swell pain leg ( ) , even skin ulcer around ankle . If clots form leg surgery , break , move lung block pulmonary artery ( also call Pulmonary Emboli PE ) . With PE chest pain , chest tightness , shortness breath , cough blood , heart failure , occasionally death . Doctors study way reduce complication . These study lead development drug interfere body 's clotting process . However , still unclear drug drug schedule best . This study evaluate two standard FDA approve drug use different dosing schedule .</brief_summary>
	<brief_title>Prophylaxis Against DVTs After Primary Hip Knee Replacement Surgery</brief_title>
	<detailed_description>Inclusion Criteria : 1 . Planned elective primary arthroplasty knee hip disease New England Baptist Hospital . 2 . Over 20 year age . 3 . Normal baseline platelet count , prothrombin partial thromboplastin time . 4 . Signed consent . Exclusion Criteria : 1 . Surgery acute fracture ( &lt; 4 week ) , septic joint , extraction arthroplasty . 2 . Patients personal history TED , document hypercoagulation disease . 3 . Increased risk hemorrhage , active gastric ulcer , bleed diathesis ; persistent intestinal urinary tract bleed within last year . SPECIFIC AIMS : This prospective , randomize study seek determine advantage fix , low dose warfarin Thromboembolic Disease ( TED ) prophylaxis among patient undergo elective low extremity joint arthroplasty , compare variable dose warfarin low molecular weight heparin ( LMWH ) . If confirm effective fix , low dose warfarin would almost ideal prophylaxis Deep Vein Thrombosis ( DVT ) Pulmonary Embolus ( PE ) : inexpensive , easy administer , minimal hemorrhagic potential , need minimal laboratory support . BACKGROUND AND SIGNIFICANCE : A progression study perform examine efficacy low dose warfarin . These study demonstrate low dose warfarin antithrombotic activity , little anticoagulant effect . Critical approach warfarin therapy initiate prior surgery . A summary study offer supportive conflicting data available . ( 1-9 ) 1 . Low dose warfarin ( 2mg ) dampens activate coagulation . ( 1-3 ) 2 . Two-step low dose warfarin begin 10-14 day pre-op effective prophylaxis . ( 4 ) 3 . Low dose warfarin ( 1mg ) prevents DVT 's surround central venous catheter start 3 day catheter insertion among patient high risk subclavian DVT . ( 5,6 ) 4 . Low dose warfarin ( 1mg ) start 7 day prior surgery equal variable dose warfarin TED prophylaxis follow hip arthroplasty . ( 7 ) 5 . Low dose warfarin ( 1mg ) start 7 day prior surgery effective TED prophylaxis patient hip replacement arthroplasty retrospective study 1003 patient . ( 8 ) The sentinel study use fix low dose warfarin regimen give patient extreme risk DVT . Patients require central venous catheter chemotherapy metastatic cancer participate randomize study 0.0 mg vs.1.0 mg daily warfarin start 3 day prior catheter placement . Subclavian vein venogram perform time symptom subclavian vein DVT 90 day . When use low dose warfarin schedule reduction incidence thrombosis 37.5 % 9.5 % . ( p &lt; 0.05 ) Four patient acquire vitamin K-responsive prolongation PT due concomitant advance liver disease and/or malnutrition . Concentrations factor II , VII , IX , X , protein C show difference treat untreated patient . ( 5 ) Two orthopedic surgery study NEBH question publish . ( 7,8 ) The first pilot study 100 patient demonstrate difference effectiveness low fix dose variable dose warfarin population patient high risk TED ( 7 ) Patients study plan total hip replacement arthroplasty randomize standard regimens use warfarin 5 mg night prior surgery follow variable dose ( target PT 1.3 - 1.5 time normal ) 30-45 day , experimental regimen use 1 mg begin 7 day prior surgery continued follow 30-45 day . Ultrasounds deep vein leg perform baseline , discharge follow surgery , 30-45 day follow-up . There difference group incidence venous thrombosis . The second study retrospective study patient undergoing primary ( 833 ) revision ( 170 ) hip replacement arthroplasty receive 1 mg warfarin 7 day surgery , variable dose hospital , ( INR target 1.5 - 2.0 ) follow 1 mg daily follow-up 30-45 day . ( 8 ) Each patient use pneumatic follow elastic compression stocking . Of 1003 patient , 9 lose follow-up . Three patient TED , include 1 PE 2 DVT .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Planned elective arthroplasty knee hip disease . 2 . Over 20 year age . 3 . Normal baseline platelet count , prothrombin partial thromboplastin time . 4 . Signed consent . 1 . Surgery acute fracture ( &lt; 4 week ) , septic joint , extraction arthroplasty . 2 . Patients personal history TED , document hypercoagulation disease . 3 . Increased risk hemorrhage , active gastric ulcer , bleed diathesis ; persistent intestinal urinary tract bleed within last year . 4 . Hemorrhagic stroke ; brain , spinal , ophthalmologic surgery previous 6 month . 5 . Liver enzymes bilirubin great 2 x normal . 6 . Decreased renal function GFR &lt; 30ml/min . ( 2427 ) 7 . Cancer last 1 year , localize cancer skin . 8 . Requires chronic anticoagulation warfarin heparin . 9 . Requires chronic platelet function suppressive therapy coronary peripheral artery stents.. 10 . Prior adverse reaction study drug . 11 . Pregnancy 12 . Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Deep Vein Thrombosis , anticoagulant , surgery , pulmonary embolus , warfarin , fondaparinox</keyword>
</DOC>